One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found.
New onset chronic kidney disease (CKD) in people with diabetes is highest among racial and ethnic minority groups compared with white persons, a UCLA-Providence study finds. The study, published as a letter to the editor in the New England Journal of Medicine, found that new onset CKD rates were higher by approximately 60%, 40%, 33%, and 25% in the Native Hawaiian/Pacific Islander, Black, American Indian/Alaska Native, and Hispanic/Latino populations, respectively, compared to white persons with diabetes.
The more hours someone works each week in a stressful job, the more their risk of depression rises, a study in new doctors finds. Working 90 or more hours a week was associated with changes in depression symptom scores three times larger than the change in depression symptoms among those working 40 to 45 hours a week. And a higher percentage of those who worked a large number of hours had scores high enough to qualify for a diagnosis of moderate to severe depression
In a set of identical twins, investigators have discovered a disease that affects the mitochondria, or the specialized compartments within cells that produce energy
A device known as a bionic pancreas, which uses next-generation technology to automatically deliver insulin, was more effective at maintaining blood glucose (sugar) levels within normal range than standard-of-care management among people with type 1 diabetes, a new multicenter clinical trial has found.
ACS recognizes global discrepancies in cancer screening recommendations across countries but remains committed to supporting U.S. evidence-based recommendations and practices based on decades of research, including the use of colonoscopy to screen for colorectal cancer.
T cells engineered to target the cell protein GPRC5D produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study in the New England Journal of Medicine.
Um novo tipo de cardioversor desfibrilador implantável (CDI) extravascular usando um eletrodo (um fio fino) colocado atrás do esterno cumpre os objetivos de segurança e eficácia em participantes de estudo clínico global antes do lançamento no mercado. O dispositivo interrompeu com eficiência arritmias ventriculares agudas e crônicas potencialmente fatais. As descobertas foram apresentadas durante uma sessão de última hora no Congresso da Sociedade Europeia de Cardiologia e publicados no The New England Journal of Medicine simultaneamente.
Un nuevo tipo de desfibrilador cardioversor implantable (ICD, por sus siglas en inglés) extravascular que emplea un cable (un alambre delgado) detrás del esternón cumplió con los objetivos de seguridad y efectividad en los participantes de un estudio clínico global previo a la comercialización. El dispositivo eliminó efectivamente arritmias ventriculares agudas y crónicas que podrían ser mortales. Los resultados se presentaron durante el Congreso de la Sociedad Europea de Cardiología y simultáneamente se publicó en The New England Journal of Medicine (Revista de Medicina de Nueva Inglaterra).
An international phase 3 clinical trial for a rare, inherited form of ALS led by Washington University School of Medicine in St. Louis, showed that an investigational drug, known as tofersen, reduced molecular signs of the fatal disease, but at six months did not improve motor control and muscle strength. However, the trial, which was sponsored by the pharmaceutical company Biogen, found evidence that longer-term use of the drug may help stabilize muscle strength and control.
A study published today in the New England Journal of Medicine (NEJM) found that among patients with aortic stenosis undergoing transfemoral TAVR, the use of a debris capturing device called cerebral embolic protection reduced the risk of disabling stroke from 1.3% to 0.5%.
Bloodstream levels of a protein fragment called endotrophin can be used to predict outcomes in patients with a common form of heart failure, according to a study co-led by researchers at the Perelman School of Medicine at the University of Pennsylvania.
In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3% of patients with stage II–IV cutaneous squamous cell carcinoma (CSCC) saw their tumors nearly or completely disappear when treated with immunotherapy before surgery.
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.
Neutralizing antibody levels against the original COVID-19 virus and omicron variants in vaccinated adults tend to decline by at least 15% per month after a single booster shot, a new study using serum from human blood samples suggests.
Dolutegravir-based antiretroviral therapy (ART) for HIV-1 infection is more effective in pregnancy than some other ART regimens commonly used in the U.S. and Europe, according to a study published in the New England Journal of Medicine.
New commentary from experts at Penn Medicine and Children's Hospital of Philadelphia outlines how health systems can help build black wealth, including helping people connect to key services.
A new type of extravascular implantable cardioverter-defibrillator (ICD) using a lead (thin wire) placed behind the sternum met safety and effectiveness goals for participants in a premarket global clinical study. The device effectively terminated acute and chronic life-threatening ventricular arrhythmias. The findings were presented during a late-breaking session at the European Society of Cardiology Congress and were simultaneously published in The New England Journal of Medicine.
A three-drug medication known as a “polypill,” developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.
Lessons learned from the public health responses to the HIV and COVID-19 pandemics should help guide the response to the current outbreak of monkeypox, National Institutes of Health experts write in an editorial published today in the New England Journal of Medicine.
Published in the New England Journal of Medicine, researchers — led by the University of Minnesota Medical School and School of Public Health — have found that metformin, a commonly prescribed diabetes medication, lowers the odds of emergency department visits, hospitalizations, or death due to COVID-19 by over 40 percent; and over 50 percent if prescribed early in onset of symptoms.
A new report on lung transplantation success rates confirms that Cedars-Sinai patients experienced one-year survival outcomes of 91.49%, an achievement above the national average of 89.46%.
A new randomized controlled study showed, however, that leaving these asymptomatic stones behind significantly increases the risk of a patient's relapse in the following five years. The findings were published today in the New England Journal of Medicine.
One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.
Although vitamin D supplements are widely prescribed and used to benefit bone health, definitive data on whether these supplements reduce fractures in the general population have been inconsistent.
Adding erythropoietin to cooling therapy for term newborns with birth asphyxia has no benefit over cooling therapy alone, a study published today in the New England Journal of Medicine.
The findings contrast with results from small trials in which erythropoietin appeared safe and effective, noted Dr. Sandra “Sunny” Juul, senior author of the study. The Alan Hodson Endowed Professor of Pediatrics at the UW School of Medicine, Juul is also the UW Medicine chief of neonatology (newborn medical care) and practices at Seattle Chldren's.
Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug.
A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Results of the research were presented by Stephen Ansell, M.D., Ph.D., at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago and were published today in the New England Journal of Medicine.
Researchers at Saint Louis University's School of Medicine, in collaboration with Arrowhead Pharmaceuticals and Takeda Pharmaceuticals, report the first effective drug to treat a rare, genetic liver disease that formerly could only be treated with a liver transplant.
In a new study sponsored by the Centers for Disease Control and Prevention and published in the New England Journal of Medicine, researchers provide additional evidence that COVID-19 vaccination during pregnancy helps protect babies younger than 6 months from being hospitalized due to COVID-19. The risk of COVID-19 hospitalization among babies was reduced by about 80 percent during the Delta wave (July 1–December 18, 2021) and 40 percent during the Omicron wave (December 19–March 8, 2022).
In a letter published in the New England Journal of Medicine, physician-scientists report that the three Omicron subvariants currently dominant in the United States – officially known as subvariants BA.2.12.1, BA.4, and BA.5 – substantially escape neutralizing antibodies induced by both vaccination and previous infection.
Six months ago, University of Maryland School of Medicine surgeon-scientists successfully implanted a genetically modified pig heart into a 57 year-old patient with terminal heart disease in a first-of-its-kind surgery.
A new perspective by researchers from the American Cancer Society and the University of Texas Health Science Center at San Antonio shows the high burden of breast cancer mortality in African American (Black) women versus White women began in the United States in the 1980’s.
A decade after the conflicts in Iraq and Afghanistan, some veterans find themselves with mysterious lung issues, seemingly attributable to exposure to burn pits.
A new study from UCLA researchers indicates a previously undocumented impact of the promotion of Covid-19 vaccines on other public health behaviors. Adult flu vaccination rates have declined in states with low rates of Covid-19 vaccination, which the authors say may be a harbinger of declining trust in public health and could make some populations more vulnerable to preventable disease.
CTE, or chronic traumatic encephalopathy, is uncommon in service members, and is more strongly linked to civilian traumatic brain injuries, according to a study published in the New England Journal of Medicine on June 9 by researchers at the Uniformed Services University of the Health Sciences. The study, “Chronic Traumatic Encephalopathy in the Brains of Military Personnel,” was led by Dr. David Priemer, assistant professor of Pathology at USU and neuropathologist for the Henry M. Jackson Foundation for the Advancement of Military Medicine, and Dr. Dan Perl, professor of Pathology and director of the Department of Defense/USU Brain Tissue Repository at USU.
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
A multi-institutional, international study, led by researchers at the Johns Hopkins Kimmel Cancer Center and WEHI in Melbourne, Australia, found that testing for ctDNA after surgery and directing chemotherapy to ctDNA-positive patients reduced the use of chemotherapy overall without compromising recurrence-free survival.
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The study results also were published today in the New England Journal of Medicine.
A case report published in the New England Journal of Medicine provides evidence that enterovirus D68 directly infects spinal cord neurons and that a corresponding robust immune response is present – a direct causation to the polio-like paralyzing illness, acute flaccid myelitis (AFM). Matthew Vogt, MD, PhD, assistant professor of pediatrics and microbiology & immunology at the UNC School of Medicine is the lead author of the study.
Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow - and increasingly in other diseases, but their mechanism of action remains unclear.
A COVID-19 booster shot will provide strong and broad antibody protection against the range of omicron sublineage variants of the SARS-CoV-2 virus in circulation, two new studies using serum from human blood samples suggest.